Trials / Completed
CompletedNCT05642585
A Study of Single-dose MY008211A in Healthy Adults
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Doses Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic/Pharmacodynamics Characteristics of MY008211A Tablets in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The trial is the first human trial. The safety, tolerability, PK and PD of MY008211A Tablets will be evaluated in healthy subjects.
Detailed description
This is a single ascending dose, randomized, double-blind study，with 5 dose groups preset.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MY008211A tablets | Single oral |
| DRUG | Placebo | Single oral |
Timeline
- Start date
- 2022-05-27
- Primary completion
- 2023-06-04
- Completion
- 2023-06-04
- First posted
- 2022-12-08
- Last updated
- 2023-09-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05642585. Inclusion in this directory is not an endorsement.